Disc Medicine Business Summary

Disc Medicine, Inc. (IRON) is a clinical-stage biopharmaceutical company that operates without current product revenue, deriving its value from a specialized pipeline targeting fundamental biological pathways in hematology, specifically heme biosynthesis and iron homeostasis. The company’s business model is predicated on the clinical advancement and eventual commercialization of its three core therapeutic candidates: bitopertin (for erythropoietic porphyrias), DISC-0974 (for anemia of myelofibrosis and chronic kidney disease), and DISC-3405 (for polycythemia vera). As of February 2026, Disc is navigating a strategic pivot following a Complete Response Letter (CRL) from the FDA regarding bitopertin’s accelerated approval; the company is now focused on the Phase 3 APOLLO trial, with topline data expected in Q4 2026 to support a traditional approval filing. Disc Medicine competes with biotechnology peers such as Avidity Biosciences, Axsome Therapeutics, Arrowhead Pharmaceuticals, and Abivax, positioning itself as a specialized mid-cap player focused on niche rare-blood-disorder markets where it seeks to establish first-in-class dominance. The executive team is led by President and CEO John Quisel, J.D., Ph.D., who previously served as Chief Business Officer at Akebia Therapeutics, alongside CFO Jean Franchi, a veteran of Replimune and Merrimack Pharmaceuticals. The leadership bench includes CTO Rahul Kaushik, COO Jonathan Yu, and CMO William Savage, M.D., Ph.D., with the recent January 2026 addition of Lisa Amaya Price as Chief Human Resources Officer from Deciphera. The company was founded by Brian MacDonald, a physician-scientist with a background in immunology, who serves as Chair of the Scientific Advisory Board alongside Executive Chairman Donald Nicholson. Disc Medicine is supported by a high-conviction group of institutional investors and board representatives from premier life science venture firms, including Atlas Venture, RA Capital Management, Frazier Life Sciences, OrbiMed, and Fidelity Management & Research Company (FMR).